查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493188

组合药物市场规模、份额、趋势分析报告：依产品、地区、细分市场预测，2024-2030

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

组合药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球组合药物市场规模将达2,518.7亿美元，2024年至2030年复合年增长率为9.0%。

由于与微创技术相关的患者治疗效果的改善，需求不断增长，这是该市场的一个有影响力的驱动力。这些设备有助于早期诊断并缩短大多数外科手术的治疗时间。需求增加的另一个原因是这些设备所提供的疼痛最小化、成本效率提高、安全性提高、疗效提高、恢復更快、住院时间缩短。

医疗保健监管机构越来越多地执行明确的上市前核准通讯协定，预计将支持製造商获得其产品的核准。最近，美国FDA采用了精益管理流程映射方法，以创建一个更具凝聚力、精简、系统和协作的系统来审查上述产品。这些当局发布的安全指南和建议预计将在未来增加这些产品的采用，从而促进其在预测期内的整体成长。

由于药物在体内非预期部位吸收而导致的与治疗药物相关的严重副作用和药物交互作用预计将引发对标靶治疗的需求，从而推动对药物-器械组合的需求。例如，连续施用左旋多巴会导致长期併发症，例如运动波动、运动障碍、严重的代谢变化和神经毒性。这些因素使得临床迫切需要采用基于标靶治疗的替代方案，例如药物-器械组合产品。

组合药物市场报告亮点

  • 由于需要长期治疗的疾病的自我给药需求不断增加，经皮贴片在 2023 年的产品市场份额中占据主导地位。
  • 从2023年的地区份额来看，北美地区所占份额最大，超过41.31%，因为该地区的主要企业正在进行广泛的新产品开发活动。
  • 由于医疗保健支出的增加以及医生对这些产品益处的意识层级的提高，预计亚太地区未来几年将以有利的速度增长。
  • 主要市场参与者正在采取各种策略，例如新产品发布和销售合作伙伴关係，以提高市场渗透率。
  • 由于较高的营运成本、严格的法律规范和资本要求，预计新进入者的威胁较低。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 复方药物市场的变数与趋势

  • 市场体系展望
  • 市场动态
    • 市场驱动因素影响分析
    • 市场限制因素影响分析
    • 市场机会影响分析
  • 产业分析工具
    • 波特的分析
    • 宏观经济分析

第四章 组合药物市场：产品分析

  • 2023 年产品变化分析与市场占有率
  • 副产品
  • 点滴帮浦
  • 整形外科组合产品
  • 动态治疗仪
  • 经皮吸收贴片
  • 药物释放型支架
  • 创伤护理产品
  • 吸入
  • 抗菌导管
  • 其他的

第五章 组合药市场：区域估计与趋势分析

  • 组合药物市场：区域前景
  • 北美洲
    • 2018-2030 年北美组合药物市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲组合药物市场估计与预测
    • 德国
    • 英国
    • 法国
  • 亚太地区
    • 2018-2030 年亚太地区复方药物市场估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲组合药物市场估计与预测
    • 巴西
    • 墨西哥
  • 中东/非洲
    • 2018-2030年中东和非洲组合药物市场估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争分析

  • 公司分类
  • 参与者概览
  • 财务绩效
  • 产品基准
  • 企业市场：定位分析
  • 策略规划
    • 併购
    • 伙伴关係与协作
    • 产品上市和监管核准
    • 扩张
  • 公司简介
    • Abbott
    • Terumo Medical Corporation
    • Stryker
    • Viatris Inc.
    • Medtronic
    • Boston Scientific Corporation
    • Novartis AG
    • Becton
    • Dickinson and company
    • Teleflex Incorporation

第七章 分析师观点

Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends:

The global drug device combination products market size is expected to reach USD 251.87 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights:

  • Transdermal patch held the dominant share by product in 2023 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • North America held the largest share of over 41.31% in 2023 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
  • 1.2. Market Definition
    • 1.2.1. Product
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objectives 1
    • 1.10.2. Objectives 2
    • 1.10.3. Objectives 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot (Regional)
  • 2.2. Segment Snapshot (Product)
  • 2.3. Competitive Landscape

Chapter 3. Drug Device Combination Products Market Variables, and Trends

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver impact analysis
      • 3.2.1.1. Increasing demand for minimally invasive drug delivery devices
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increasing prevalence of chronic diseases
    • 3.2.2. Market Restraint Impact Analysis
      • 3.2.2.1. High cost associated with drug device combination products
      • 3.2.2.2. Technical challenges in drug delivery
      • 3.2.2.3. Increasing prevalence of chronic diseases
    • 3.2.3. Market Opportunity Impact Analysis
      • 3.2.3.1. Growing adherence rate
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's analysis
    • 3.3.2. Macroeconomics analysis

Chapter 4. Drug Device Combination Product Market: Product Analysis

  • 4.1. Product Movement Analysis & Market Share, 2023
  • 4.2. Drug Device Combination Products Market: Estimates & Forecast, By Product (USD Billion)
    • 4.2.1. Infusion Pumps
      • 4.2.1.1. Infusion pumps market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Volumetric
      • 4.2.1.2.1. Volumetric market, 2018 - 2030 (USD Million)
      • 4.2.1.3. Disposables
      • 4.2.1.3.1. Disposables market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Syringes
      • 4.2.1.4.1. Syringes market, 2018 - 2030 (USD Million)
      • 4.2.1.5. Ambulatory
      • 4.2.1.5.1. Ambulatory market, 2018 - 2030 (USD Million)
      • 4.2.1.6. Implantable
      • 4.2.1.6.1. Implantable market, 2018 - 2030 (USD Million)
      • 4.2.1.7. Insulin
      • 4.2.1.7.1. Insulin market, 2018 - 2030 (USD Million)
    • 4.2.2. Orthopedic combination products
      • 4.2.2.1. Orthopedic combination product market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Bone Graft Implants
      • 4.2.2.2.1. Bone graft implant market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Antibiotic Bone Cement
      • 4.2.2.3.1. Antibiotic bone cement market, 2018 - 2030 (USD Million)
    • 4.2.3. Photodynamics therapy devices
      • 4.2.3.1. Photodynamics therapy devices market, 2018 - 2030 (USD Million)
    • 4.2.4. Transdermal patches
      • 4.2.4.1. Transdermal patches market, 2018 - 2030 (USD Million)
    • 4.2.5. Drug eluting stents
      • 4.2.5.1. Drug eluting stents market, 2018 - 2030 (USD Million)
      • 4.2.5.2. Coronary Stents
      • 4.2.5.2.1. Coronary Stents market, 2018 - 2030 (USD Million)
      • 4.2.5.3. Peripheral vascular stents
      • 4.2.5.3.1. Peripheral vascular stents market, 2018 - 2030 (USD Million)
    • 4.2.6. Wound care products
      • 4.2.6.1. Wound care product market, 2018 - 2030 (USD Million)
    • 4.2.7. Inhalers
      • 4.2.7.1. Inhalers market, 2018 - 2030 (USD Million)
      • 4.2.7.2. Dry powder
      • 4.2.7.2.1. Dry powder market, 2018 - 2030 (USD Million)
      • 4.2.7.3. Nebulizers
      • 4.2.7.3.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 4.2.7.4. Metered Dose
      • 4.2.7.4.1. Metered Dose market, 2018 - 2030 (USD Million)
    • 4.2.8. Antimicrobial catheters
      • 4.2.8.1. Antimicrobial catheters market, 2018 - 2030 (USD Million)
      • 4.2.8.2. Urological
      • 4.2.8.2.1. Urological market, 2018 - 2030 (USD Million)
      • 4.2.8.3. Cardiovascular
      • 4.2.8.3.1. Cardiovascular market, 2018 - 2030 (USD Million)
      • 4.2.8.4. Others
      • 4.2.8.4.1. Others market, 2018 - 2030 (USD Million)
    • 4.2.9. Others
      • 4.2.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Drug Device Combination Products Market: Regional Estimates & Trend Analysis

  • 5.1. Drug Device Combination Products Market: Regional Outlook
  • 5.2. North America
    • 5.2.1. North America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key country dynamics
      • 5.2.2.2. Competitive scenario
      • 5.2.2.3. Regulatory scenario
      • 5.2.2.4. Reimbursement scenario
      • 5.2.2.5. U.S. drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key country dynamics
      • 5.2.3.2. Competitive scenario
      • 5.2.3.3. Regulatory scenario
      • 5.2.3.4. Reimbursement scenario
      • 5.2.3.5. Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2. Germany
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Competitive scenario
      • 5.3.2.3. Regulatory scenario
      • 5.3.2.4. Reimbursement scenario
      • 5.3.2.5. Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Competitive scenario
      • 5.3.3.3. Regulatory scenario
      • 5.3.3.4. Reimbursement scenario
      • 5.3.3.5. UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Competitive scenario
      • 5.3.4.3. Regulatory scenario
      • 5.3.4.4. Reimbursement scenario
      • 5.3.4.5. France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Competitive scenario
      • 5.4.2.3. Regulatory scenario
      • 5.4.2.4. Reimbursement scenario
      • 5.4.2.5. Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Competitive scenario
      • 5.4.3.3. Regulatory scenario
      • 5.4.3.4. Reimbursement scenario
      • 5.4.3.5. China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Competitive scenario
      • 5.4.4.3. Regulatory scenario
      • 5.4.4.4. Reimbursement scenario
      • 5.4.4.5. India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Competitive scenario
      • 5.4.5.3. Regulatory scenario
      • 5.4.5.4. Reimbursement scenario
      • 5.4.5.5. Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. South Korea
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Competitive scenario
      • 5.4.6.3. Regulatory scenario
      • 5.4.6.4. Reimbursement scenario
      • 5.4.6.5. South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Competitive scenario
      • 5.5.2.3. Regulatory scenario
      • 5.5.2.4. Reimbursement scenario
      • 5.5.2.5. Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Competitive scenario
      • 5.5.3.3. Regulatory scenario
      • 5.5.3.4. Reimbursement scenario
      • 5.5.3.5. Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East & Africa
    • 5.6.1. Middle East & Africa drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Competitive scenario
      • 5.6.2.3. Regulatory scenario
      • 5.6.2.4. Reimbursement scenario
      • 5.6.2.5. South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Competitive scenario
      • 5.6.3.3. Regulatory scenario
      • 5.6.3.4. Reimbursement scenario
      • 5.6.3.5. Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Competitive scenario
      • 5.6.4.3. Regulatory scenario
      • 5.6.4.4. Reimbursement scenario
      • 5.6.4.5. UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Competitive scenario
      • 5.6.5.3. Regulatory scenario
      • 5.6.5.4. Reimbursement scenario
      • 5.6.5.5. Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Analysis

  • 6.1. Company Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Performance
  • 6.4. Product Benchmarking
  • 6.5. Company Market: Position Analysis
  • 6.6. Strategy Mapping
    • 6.6.1. Mergers & acquisitions
    • 6.6.2. Partnerships & collaborations
    • 6.6.3. Product launch & regulatory approval
    • 6.6.4. Expansion
  • 6.7. Company Profiles
    • 6.7.1. Abbott
      • 6.7.1.1. Company Overview
      • 6.7.1.2. Financial Performing
      • 6.7.1.3. Product Benchmarking
      • 6.7.1.4. Strategic Initiatives
    • 6.7.2. Terumo Medical Corporation
      • 6.7.2.1. Company Overview
      • 6.7.2.2. Financial Performing
      • 6.7.2.3. Product Benchmarking
      • 6.7.2.4. Strategic Initiatives
    • 6.7.3. Stryker
      • 6.7.3.1. Company Overview
      • 6.7.3.2. Financial Performing
      • 6.7.3.3. Product Benchmarking
      • 6.7.3.4. Strategic Initiatives
    • 6.7.4. Viatris Inc.
      • 6.7.4.1. Company Overview
      • 6.7.4.2. Financial Performing
      • 6.7.4.3. Product Benchmarking
      • 6.7.4.4. Strategic Initiatives
    • 6.7.5. Medtronic
      • 6.7.5.1. Company Overview
      • 6.7.5.2. Financial Performing
      • 6.7.5.3. Product Benchmarking
      • 6.7.5.4. Strategic Initiatives
    • 6.7.6. Boston Scientific Corporation
      • 6.7.6.1. Company Overview
      • 6.7.6.2. Financial Performing
      • 6.7.6.3. Product Benchmarking
      • 6.7.6.4. Strategic Initiatives
    • 6.7.7. Novartis AG
      • 6.7.7.1. Company Overview
      • 6.7.7.2. Financial Performing
      • 6.7.7.3. Product Benchmarking
      • 6.7.7.4. Strategic Initiatives
    • 6.7.8. Becton
      • 6.7.8.1. Company Overview
      • 6.7.8.2. Financial Performing
      • 6.7.8.3. Product Benchmarking
      • 6.7.8.4. Strategic Initiatives
    • 6.7.9. Dickinson and company
      • 6.7.9.1. Company Overview
      • 6.7.9.2. Financial Performing
      • 6.7.9.3. Product Benchmarking
      • 6.7.9.4. Strategic Initiatives
    • 6.7.10. Teleflex Incorporation
      • 6.7.10.1. Company Overview
      • 6.7.10.2. Financial Performing
      • 6.7.10.3. Product Benchmarking
      • 6.7.10.4. Strategic Initiatives

Chapter 7. Analysis Perspective

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Drug device combination products market revenue estimates and forecast, by product, 2018 - 2030 (USD Billion)
  • Table 4 U.S. regulatory procedure for medical devices
  • Table 5 Canada regulatory procedure for medical devices
  • Table 6 Classification of medical devices

List of Figures

  • Fig. 1 Drug device combination products market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot, USD Million
  • Fig. 9 Segment snapshot (Product)
  • Fig. 10 Competitive landscape
  • Fig. 11 Drug delivery devices and drug device combination products market value, 2023 (USD million)
  • Fig. 12 Drug device combination products market dynamics
  • Fig. 13 Diabetes around the world in 2021, (Million)
  • Fig. 14 Estimated number of U.S. hospital hip and knee replacement procedures: (2021 - 2022)
  • Fig. 15 Drug device combination products market: PORTER's analysis
  • Fig. 16 Drug device combination products market: PESTEL analysis
  • Fig. 17 Drug device combination product market: Product outlook and key takeaways
  • Fig. 18 Drug device combination products market, by product: Market share, 2023 & 2030
  • Fig. 19 Infusion pumps market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Volumetric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Disposables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Syringes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Ambulatory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Implantable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Orthopedic combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Bone graft implants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Antibiotic bone cement market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Photodynamic therapy devices market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Transdermal patches market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Drug eluting stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Coronary stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Peripheral vascular stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Wound care products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Inhalers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Dry powder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Nebulizers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Metered dose market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Antimicrobial catheters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Urological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Drug device combination products market revenue, by region, 2023 & 2030 (USD Billion)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Reimbursement procurement process
  • Fig. 49 US drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Reimbursement procurement process
  • Fig. 62 Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Middle East & Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategy mapping